Abbott Laboratories Change in Accounts Payable 2010-2025 | ABT
Abbott Laboratories annual/quarterly change in accounts payable history and growth rate from 2010 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
- Abbott Laboratories change in accounts payable for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Abbott Laboratories change in accounts payable for the twelve months ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Abbott Laboratories annual change in accounts payable for 2024 was $0B, a 0% decline from 2023.
- Abbott Laboratories annual change in accounts payable for 2023 was $0B, a 0% decline from 2022.
- Abbott Laboratories annual change in accounts payable for 2022 was $0B, a 0% decline from 2021.
| Abbott Laboratories Annual Change in Accounts Payable (Millions of US $) |
|
|---|---|
| 2024 | $N/A |
| 2023 | $N/A |
| 2022 | $N/A |
| 2021 | $N/A |
| 2020 | $N/A |
| 2019 | $N/A |
| 2018 | $N/A |
| 2017 | $N/A |
| 2016 | $N/A |
| 2015 | $N/A |
| 2014 | $N/A |
| 2013 | $N/A |
| 2012 | $N/A |
| 2011 | $N/A |
| 2010 | $N/A |
| 2009 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $232.442B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $153.655B | 38.47 |
| Stryker (SYK) | United States | $150.679B | 31.51 |
| EssilorLuxottica (ESLOY) | France | $135.238B | 0.00 |
| Medtronic (MDT) | Ireland | $114.659B | 16.25 |
| Lonza Group Ag (LZAGY) | Switzerland | $51.418B | 0.00 |
| Haleon (HLN) | United Kingdom | $45.416B | 25.92 |
| ResMed (RMD) | United States | $37.840B | 28.42 |
| Agilent Technologies (A) | United States | $35.272B | 22.99 |
| GE HealthCare Technologies (GEHC) | United States | $35.028B | 16.63 |
| Terumo (TRUMY) | Japan | $24.711B | 32.10 |
| Koninklijke Philips (PHG) | Netherlands | $23.746B | 16.66 |
| Insulet (PODD) | United States | $20.930B | 82.15 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.825B | 12.09 |
| Baxter (BAX) | United States | $15.241B | 11.38 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.608B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.072B | 24.61 |
| Lantheus Holdings (LNTH) | United States | $5.800B | 14.63 |
| Prestige Consumer Healthcare (PBH) | United States | $3.832B | 17.12 |
| Haemonetics (HAE) | United States | $3.755B | 17.10 |
| Perrigo (PRGO) | Ireland | $3.749B | 9.50 |
| Envista Holdings (NVST) | United States | $3.512B | 29.18 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.378B | 24.91 |
| QuidelOrtho (QDEL) | United States | $2.134B | 14.67 |
| LeMaitre Vascular (LMAT) | United States | $1.937B | 43.31 |
| AtriCure (ATRC) | United States | $1.587B | 0.00 |
| Acuren (TIC) | United States | $1.427B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.357B | 30.52 |
| AdaptHealth (AHCO) | United States | $1.275B | 12.94 |
| Phibro Animal Health (PAHC) | United States | $1.262B | 16.14 |
| Neogen (NEOG) | United States | $1.211B | 15.50 |
| BioLife Solutions (BLFS) | United States | $1.087B | 0.00 |
| InMode (INMD) | Israel | $0.960B | 9.67 |
| Curaleaf Holdings (CURLF) | Canada | $0.818B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $0.780B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.736B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.641B | 0.00 |
| Owens & Minor (OMI) | United States | $0.640B | 5.31 |
| Evolus (EOLS) | United States | $0.627B | 0.00 |
| CeriBell (CBLL) | United States | $0.606B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.521B | 0.00 |
| Valneva SE (VALN) | France | $0.511B | 0.00 |
| Surmodics (SRDX) | United States | $0.444B | 0.00 |
| SNDL (SNDL) | Canada | $0.373B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.352B | 12.94 |
| Cresco Labs (CRLBF) | United States | $0.342B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.307B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Cerus (CERS) | United States | $0.296B | 0.00 |
| Quanterix (QTRX) | United States | $0.292B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.276B | 23.27 |
| Sanara MedTech (SMTI) | United States | $0.273B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.264B | 78.17 |
| ZimVie (ZIMV) | United States | $0.262B | 11.90 |
| Brainsway (BWAY) | Israel | $0.239B | 63.17 |
| Biote (BTMD) | United States | $0.230B | 6.48 |
| OraSure Technologies (OSUR) | United States | $0.228B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.225B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.219B | 0.00 |
| Omeros (OMER) | United States | $0.203B | 0.00 |
| Organigram Global (OGI) | Canada | $0.197B | 0.00 |
| High Tide (HITI) | Canada | $0.194B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.189B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.186B | 15.14 |
| Vireo Growth (VREOF) | United States | $0.164B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.124B | 15.25 |
| TerrAscend (TSNDF) | Canada | $0.115B | 0.00 |
| Fonar (FONR) | United States | $0.100B | 12.91 |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.098B | 0.00 |
| Jin Medical (ZJYL) | China | $0.095B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Veru (VERU) | United States | $0.085B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.083B | 0.00 |
| Apyx Medical (APYX) | United States | $0.082B | 0.00 |
| InterCure (INCR) | Israel | $0.073B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.071B | 0.00 |
| Agape ATP (ATPC) | $0.071B | 0.00 | |
| Zynex (ZYXI) | United States | $0.070B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.044B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| Nephros (NEPH) | United States | $0.040B | 53.57 |
| United-Guardian (UG) | United States | $0.038B | 13.02 |
| Safety Shot (SHOT) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.022B | 0.00 |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.015B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Senestech (SNES) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |